drugset

drugset / Trial / NCT02444234

Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis

NCT02444234 ↗

Phase 4 Completed 11 enrolled University of Southern California Merck Sharp & Dohme LLC · collab

RandomizedCrossoverOpen-labelOther

Summary

The proposed study is designed to characterize the pharmacokinetics of intravenous and oral tedizolid in patients with Cystic Fibrosis.

Timeline

Start: 2015-07
Primary completion: 2017-12-31
Completion: 2017-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tedizolid	Small molecule	200 mg	Oral

Indications